Efficacy and Safety of Drug-coated Balloons in Chronic Total Coronary Occlusion Recanalization: a Systematic Review and Meta-analysis

Overview

Journal BMC Cardiovasc Disord

Publisher Biomed Central

Specialty Cardiology & Vascular Diseases

Date 2024 Jun 25

PMID 38918738

Authors

Yuhao Zhao

Ping Wang

Ze Zheng

Qin Ma

Yuchen Shi

Jinghua Liu

Affiliations

Soon will be listed here.

Abstract

Background: With advancements in chronic total coronary occlusion (CTO) recanalization techniques and concepts, the success rate of recanalization has been steadily increasing. However, the current data are too limited to draw any reliable conclusions about the efficacy and safety of drug-coated balloons (DCBs) in CTO percutaneous coronary intervention (PCI). Herein, we conducted a meta-analysis to confirm the efficacy of DCB in CTO PCI.

Methods: We systematically searched PubMed, Web of Science and Embase from inception to July 25, 2023. The primary outcome was major advent cardiovascular events (MACE), including cardiac death, nonfatal myocardial infarction (MI), target lesion revascularization (TLR), and target vessel revascularization (TVR). The follow-up angiographic endpoints were late lumen enlargement (LLE), reocclusion and restenosis.

Results: Five studies with a total of 511 patients were included in the meta-analysis. Across studies, patients were predominantly male (72.9-85.7%) and over fifty years old. The summary estimate rate of MACE was 13.0% (95% CI 10.1%-15.9%, I = 0%, p = 0.428). The summary estimate rates of cardiac death and MI were 2.2% (95% CI 0.7%-3.7%, I = 0%, p = 0.873) and 1.2% (95% CI -0.2-2.6%, I = 13.7%, p = 0.314), respectively. Finally, the pooled incidences of TLR and TVR were 10.1% (95% CI 5.7%-14.5%, I = 51.7%, p = 0.082) and 7.1% (95% CI 3.0%-11.2%, I = 57.6%, p = 0.070), respectively. Finally, the summary estimate rates of LLE, reocclusion and restenosis were 59.4% (95% CI 53.5-65.3%, I = 0%, p = 0.742), 3.3% (95% CI 1.1-5.4%, I = 0%, p = 0.865) and 17.5% (95% CI 12.9-22.0%, I = 0%, p = 0.623), respectively.

Conclusion: Accordingly, DCB has the potential to be used as a treatment for CTO in suitable patients.

References

Buccheri D, Lombardo R, Cortese B . Drug-coated balloons for coronary artery disease: current concepts and controversies. Future Cardiol. 2019; 15(6):437-454. DOI: 10.2217/fca-2019-0009. View

Sogabe K, Koide M, Fukui K, Kato Y, Kitajima H, Akabame S . Optical coherence tomography analysis of late lumen enlargement after paclitaxel-coated balloon angioplasty for de-novo coronary artery disease. Catheter Cardiovasc Interv. 2020; 98(1):E35-E42. DOI: 10.1002/ccd.29435. View

Azzalini L, Jolicoeur E, Pighi M, Millan X, Picard F, Tadros V . Epidemiology, Management Strategies, and Outcomes of Patients With Chronic Total Coronary Occlusion. Am J Cardiol. 2016; 118(8):1128-1135. DOI: 10.1016/j.amjcard.2016.07.023. View

Konishi H, Habara M, Nasu K, Koshida R, Kinoshita Y, Tsuchikane E . Impact of Optimal Preparation Before Drug-Coated Balloon Dilatation for De Novo Lesion in Patients With Coronary Artery Disease. Cardiovasc Revasc Med. 2021; 35:91-95. DOI: 10.1016/j.carrev.2021.03.012. View

Valenti R, Vergara R, Migliorini A, Parodi G, Carrabba N, Cerisano G . Predictors of reocclusion after successful drug-eluting stent-supported percutaneous coronary intervention of chronic total occlusion. J Am Coll Cardiol. 2013; 61(5):545-50. DOI: 10.1016/j.jacc.2012.10.036. View

Levin A, Vukmirovic N, Hwang C, Edelman E . Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel. Proc Natl Acad Sci U S A. 2004; 101(25):9463-7. PMC: 438999. DOI: 10.1073/pnas.0400918101. View

Tomasello S, Boukhris M, Giubilato S, Marza F, Garbo R, Contegiacomo G . Management strategies in patients affected by chronic total occlusions: results from the Italian Registry of Chronic Total Occlusions. Eur Heart J. 2015; 36(45):3189-98. DOI: 10.1093/eurheartj/ehv450. View

Terashita K, Shimada Y, Yamanaka Y, Motohashi Y, Tonomura D, Yoshitani K . Intraplaque wiring enables drug-coated balloons to be utilized for percutaneous recanalization of chronically occluded coronary arteries. Catheter Cardiovasc Interv. 2023; 101(4):764-772. DOI: 10.1002/ccd.30596. View

Sakakura K, Nakano M, Otsuka F, Yahagi K, Kutys R, Ladich E . Comparison of pathology of chronic total occlusion with and without coronary artery bypass graft. Eur Heart J. 2013; 35(25):1683-93. PMC: 4076662. DOI: 10.1093/eurheartj/eht422. View

10.

Jeger R, Eccleshall S, Wan Ahmad W, Ge J, Poerner T, Shin E . Drug-Coated Balloons for Coronary Artery Disease: Third Report of the International DCB Consensus Group. JACC Cardiovasc Interv. 2020; 13(12):1391-1402. DOI: 10.1016/j.jcin.2020.02.043. View

11.

Yamamoto T, Sawada T, Uzu K, Takaya T, Kawai H, Yasaka Y . Possible mechanism of late lumen enlargement after treatment for de novo coronary lesions with drug-coated balloon. Int J Cardiol. 2020; 321:30-37. DOI: 10.1016/j.ijcard.2020.07.028. View

12.

Koln P, Scheller B, Liew H, Rissanen T, Wan Ahmad W, Weser R . Treatment of chronic total occlusions in native coronary arteries by drug-coated balloons without stenting - A feasibility and safety study. Int J Cardiol. 2016; 225:262-267. DOI: 10.1016/j.ijcard.2016.09.105. View

13.

Scheller B, Fischer D, Clever Y, Kleber F, Speck U, Bohm M . Treatment of a coronary bifurcation lesion with drug-coated balloons: lumen enlargement and plaque modification after 6 months. Clin Res Cardiol. 2013; 102(6):469-72. DOI: 10.1007/s00392-013-0556-3. View

14.

Wang X, Yang X, Lu W, Pan L, Han Z, Pan S . Long-term outcomes of less drug-eluting stents by the use of drug-coated balloons in coronary chronic total occlusion intervention: A multicenter observational study. Front Cardiovasc Med. 2023; 10:1045859. PMC: 10022494. DOI: 10.3389/fcvm.2023.1045859. View

15.

Rossello X, Pujadas S, Serra A, Bajo E, Carreras F, Barros A . Assessment of Inducible Myocardial Ischemia, Quality of Life, and Functional Status After Successful Percutaneous Revascularization in Patients With Chronic Total Coronary Occlusion. Am J Cardiol. 2016; 117(5):720-6. DOI: 10.1016/j.amjcard.2015.12.001. View

16.

Brilakis E, Karmpaliotis D, Vo M, Garcia S, Michalis L, Alaswad K . Advances in the management of coronary chronic total occlusions. J Cardiovasc Transl Res. 2014; 7(4):426-36. DOI: 10.1007/s12265-014-9556-6. View

17.

Scheller B, Speck U, Abramjuk C, Bernhardt U, Bohm M, Nickenig G . Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation. 2004; 110(7):810-4. DOI: 10.1161/01.CIR.0000138929.71660.E0. View

18.

Dinesch V, Buruian M . Drug-eluting stent failure: A complex scenario. Int J Cardiol. 2017; 247:26. DOI: 10.1016/j.ijcard.2017.01.058. View

19.

Giacoppo D, Alfonso F, Xu B, Claessen B, Adriaenssens T, Jensen C . Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stent Implantation in Patients With Coronary Stent Restenosis. J Am Coll Cardiol. 2020; 75(21):2664-2678. DOI: 10.1016/j.jacc.2020.04.006. View

20.

Kleber F, Schulz A, Waliszewski M, Hauschild T, Bohm M, Dietz U . Local paclitaxel induces late lumen enlargement in coronary arteries after balloon angioplasty. Clin Res Cardiol. 2014; 104(3):217-25. DOI: 10.1007/s00392-014-0775-2. View